Skip to main content
OpenTrials
Completed

NCT Number: NCT02117544

Multifocal High ADD Contact Lens Proof of Concept Trial

The purpose of this study is to evaluate the visual performance of a new multifocal High ADD contact lens compared to the currently-marketed AIR OPTIX® AQUA MULTIFOCAL (AOAMF) High ADD Contact Lens.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must sign an Informed Consent document;
  • Presbyopic and require at least 2.25 diopters (D) spectacle ADD power;
  • Current or previous soft contact lens wearer;
  • Not able to achieve monocular near visual acuity (VA) 0.2 logarithm of the Minimum Angle of Resolution (logMAR) [Early Treatment of Diabetic Retinopathy Study (ETDRS)] or better in each eye with AIR OPTIX® AQUA Multifocal (AOAMF) High ADD Contact Lenses;
  • Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial;
  • Manifest cylinder less than or equal to 1.00 D;
  • Able to achieve best corrected visual acuity (BCVA) of 20/25 or better in each eye at distance (as determined by manifest refraction);
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator;
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear;
  • Any history of herpetic keratitis;
  • History of corneal or refractive surgery, irregular cornea or unilateral pseudophakia;
  • Biomicroscopy findings (except for corneal vascularization) that are moderate (Grade 3) or severe (Grade 4);
  • Corneal vascularization that is mild (Grade 2) or higher;
  • A pathologically dry eye that precludes contact lens wear;
  • Monocular (only 1 eye with functional vision);
  • Anisometropia ≥ 1.50 D (contact lens distance prescription);
  • Clinically significant (> 1 millimeter) anisocoria;
  • History of intolerance or hypersensitivity to any component of the investigational products;
  • Concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days;
  • Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
  • Any ocular or systemic medical condition that may, in the opinion of the Investigator, preclude safe administration of the study lenses or affect the results of this study;
  • Other protocol-defined exclusion criteria may apply.

Treatment and study plan

Lotrafilcon B multifocal contact lenses (new)

Device

Lotrafilcon B multifocal contact lenses

Device

Other names: AIR OPTIX® AQUA Multifocal, AOAMF

Primary outcomes

  1. High Contrast Visual Acuity (HCVA) Near Monocular

    Time frame: Day 1, 10 minutes after lens insertion, each product

    Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HCVA was assessed monocularly (each eye separately) at 40 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.

Secondary outcomes

  1. HCVA Distance Monocular

    Time frame: Day 1, 10 minutes after lens insertion, each product

    Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HCVA was assessed monocularly (each eye separately) at 6 meters using an ETDRS chart and measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.

  2. HCVA Intermediate Monocular

    Time frame: Day 1, 10 minutes after lens insertion, each product

    Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HCVA was assessed monocularly (each eye separately) at 1 meter using an ETDRS chart and measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.

  3. Low Contrast Visual Acuity (LCVA) Distance Monocular

    Time frame: Day 1, 10 minutes after lens insertion, each product

    Visual Acuity (clarity or sharpness of vision) was measured at low contrast level. LCVA was assessed monocularly (each eye separately) at 6 meters using an ETDRS chart and measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Evaluation of Visual Performance With a Multifocal High ADD Soft Contact Lens Design

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Apr 21, 2014
Registry last updated
Aug 26, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.